PolyPid Announces Successful Completion Of Manufacturing Process Validation For D-PLEX₁₀₀
Portfolio Pulse from Benzinga Newsdesk
PolyPid Ltd. (NASDAQ:PYPD) has successfully completed the production of three process validation batches of D-PLEX100, a significant step towards the submission of D-PLEX100 New Drug Application (NDA) and Marketing Authorization Application (MAA) regulatory filings.
September 19, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PolyPid's successful completion of the production process validation for D-PLEX100 is a significant step towards regulatory filings, which could potentially boost the company's stock.
The successful completion of the production process validation for D-PLEX100 is a key milestone for PolyPid. This brings the company closer to the submission of regulatory filings, which, if approved, could significantly increase the company's market value and positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100